These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25236995)

  • 1. Validation of the IMS CORE Diabetes Model.
    McEwan P; Foos V; Palmer JL; Lamotte M; Lloyd A; Grant D
    Value Health; 2014 Sep; 17(6):714-24. PubMed ID: 25236995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).
    Willis M; Asseburg C; He J
    J Med Econ; 2013 Aug; 16(8):1007-21. PubMed ID: 23718682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the CORE Diabetes Model against epidemiological and clinical studies.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S27-40. PubMed ID: 15324514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the UKPDS Outcomes Model to predict all-cause mortality in U.S. adults with type 2 diabetes mellitus: comparison of predicted versus observed mortality.
    Song M; Alexander CM; Mavros P; Lopez VA; Malik S; Phatak HM; Wong ND
    Diabetes Res Clin Pract; 2011 Jan; 91(1):121-6. PubMed ID: 21074286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model.
    McEwan P; Ward T; Bennett H; Bergenheim K
    Cost Eff Resour Alloc; 2015; 13():12. PubMed ID: 26244041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
    Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
    Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: A modeling study.
    Quan J; Ng CS; Kwok HHY; Zhang A; Yuen YH; Choi CH; Siu SC; Tang SY; Wat NM; Woo J; Eggleston K; Leung GM
    PLoS Med; 2021 Jun; 18(6):e1003692. PubMed ID: 34166382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).
    Willis M; Johansen P; Nilsson A; Asseburg C
    Pharmacoeconomics; 2017 Mar; 35(3):375-396. PubMed ID: 27838913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
    Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
    Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus.
    Henriksson M; Jindal R; Sternhufvud C; Bergenheim K; Sörstadius E; Willis M
    Pharmacoeconomics; 2016 Jun; 34(6):569-85. PubMed ID: 26792792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.
    Laxy M; Schöning VM; Kurz C; Holle R; Peters A; Meisinger C; Rathmann W; Mühlenbruch K; Kähm K
    Pharmacoeconomics; 2019 Dec; 37(12):1485-1494. PubMed ID: 31350720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus.
    Valentine WJ; Pollock RF; Saunders R; Bae J; Norrbacka K; Boye K
    Value Health; 2017; 20(7):985-991. PubMed ID: 28712629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data.
    Lagani V; Chiarugi F; Thomson S; Fursse J; Lakasing E; Jones RW; Tsamardinos I
    J Diabetes Complications; 2015; 29(4):479-87. PubMed ID: 25772254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.
    Hayes AJ; Leal J; Gray AM; Holman RR; Clarke PM
    Diabetologia; 2013 Sep; 56(9):1925-33. PubMed ID: 23793713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Lammert M; Nicklasson L; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN).
    Schiel R; Müller UA; Braun A; Stein G; Kath R
    Eur J Med Res; 2005 Aug; 10(8):339-44. PubMed ID: 16131475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.